Mangoceuticals, Inc. (MGRX) stock

MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 7/30

$0.15−0.03 (-16.22%)

Close on Nov 13, 2026Market cap $3.34MP/E –Yield –

Mangoceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Mangoceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Mangoceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Oct 16, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing